share_log

HC Wainwright & Co. Maintains Buy on Kezar Life Sciences, Raises Price Target to $20

HC Wainwright & Co. Maintains Buy on Kezar Life Sciences, Raises Price Target to $20

HC Wainwright & Co.维持对Kezar生命科学的买入,将目标价上调至20美元
Benzinga ·  2023/09/25 06:17

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Kezar Life Sciences (NASDAQ:KZR) with a Buy and raises the price target from $18 to $20.

HC Wainwright & Co. 分析师Raghuram Selvaraju维持Kezar Life Sciences(纳斯达克股票代码:KZR)的买入,并将目标股价从18美元上调至20美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发